Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Observational
Observational Model: Cohort, Time Perspective: Prospective
Incidence of BRAF V600 mutation positivity in tumor samples
approximately 12 months
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
ML28560
NCT01804140
December 2012
August 2015
Name | Location |
---|---|
Alexandria, Minnesota 56308 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Denver, Colorado | |
Las Vegas, Nevada 89109 |